These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Pasca S; Chifotides HT; Verstovsek S; Bose P Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007 [TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
4. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511 [TBL] [Abstract][Full Text] [Related]
5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Tefferi A; Barbui T Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718 [TBL] [Abstract][Full Text] [Related]
7. Genetic Risk Assessment in Myeloproliferative Neoplasms. Tefferi A; Vannucchi AM Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261 [TBL] [Abstract][Full Text] [Related]
8. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813 [TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387 [TBL] [Abstract][Full Text] [Related]
11. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633 [TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007 [TBL] [Abstract][Full Text] [Related]
13. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria. Kvasnicka HM Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840 [TBL] [Abstract][Full Text] [Related]
14. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873 [TBL] [Abstract][Full Text] [Related]
15. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT. Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847 [TBL] [Abstract][Full Text] [Related]
16. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359 [TBL] [Abstract][Full Text] [Related]
17. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Kilpivaara O; Levine RL Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359 [TBL] [Abstract][Full Text] [Related]
19. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ha JS; Kim YK; Jung SI; Jung HR; Chung IS Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Tan YX; Xu N; Huang JX; Wu WE; Liu L; Zhou LL; Liu XL; Yin CX; Xu D; Zhou X Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):576-582. PubMed ID: 32810965 [No Abstract] [Full Text] [Related] [Next] [New Search]